Alternative Splicing: A Key Mediator of Diabetic Vasculopathy

被引:8
|
作者
Cornelius, Victoria A. [1 ]
Fulton, Jenna R. [1 ]
Margariti, Andriana [1 ]
机构
[1] Wellcome Wolfson Inst Expt Med, Belfast BT9 7BL, Antrim, North Ireland
关键词
alternative splicing; cardiovascular disease; diabetic vasculopathy; atherosclerosis; isoforms; quaking; QKI; therapeutic strategies; ENDOTHELIAL GROWTH-FACTOR; VEGF-A; CARDIOVASCULAR-DISEASE; IN-VIVO; ANGIOGENESIS; ISOFORM; MUTATIONS; QUAKING; DYSFUNCTION; EXPRESSION;
D O I
10.3390/genes12091332
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Cardiovascular disease is the leading cause of death amongst diabetic individuals. Atherosclerosis is the prominent driver of diabetic vascular complications, which is triggered by the detrimental effects of hyperglycemia and oxidative stress on the vasculature. Research has extensively shown diabetes to result in the malfunction of the endothelium, the main component of blood vessels, causing severe vascular complications. The pathogenic mechanism in which diabetes induces vascular dysfunction, however, remains largely unclear. Alternative splicing of protein coding pre-mRNAs is an essential regulatory mechanism of gene expression and is accepted to be intertwined with cellular physiology. Recently, a role for alternative splicing has arisen within vascular health, with aberrant mis-splicing having a critical role in disease development, including in atherosclerosis. This review focuses on the current knowledge of alternative splicing and the roles of alternatively spliced isoforms within the vasculature, with a particular focus on disease states. Furthermore, we explore the recent elucidation of the alternatively spliced QKI gene within vascular cell physiology and the onset of diabetic vasculopathy. Potential therapeutic strategies to restore aberrant splicing are also discussed.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Alternative RNA splicing in tumour heterogeneity, plasticity and therapy
    Pohl, Sebastian Other-Gee
    Myant, Kevin B.
    DISEASE MODELS & MECHANISMS, 2022, 15 (01)
  • [42] Function of ERBB4 is determined by alternative splicing
    Veikkolainen, Ville
    Vaparanta, Katri
    Halkilahti, Kalle
    Iljin, Kristiina
    Sundvall, Maria
    Elenius, Klaus
    CELL CYCLE, 2011, 10 (16) : 2647 - 2657
  • [43] How alternative splicing changes the properties of plant proteins
    Kashkan, Ivan
    Timofeyenko, Ksenia
    Ruzicka, Kamil
    QUANTITATIVE PLANT BIOLOGY, 2022, 3
  • [44] Occludin as a Key Mediator in Adiponectin-Mediated Diabetic Vascular Protection
    Duan, Yanru
    Du, Yunhui
    CIRCULATION, 2023, 148
  • [45] Targeting serine- and arginine-rich splicing factors to rectify aberrant alternative splicing
    Li, Dianyang
    Yu, Wenying
    Lai, Maode
    DRUG DISCOVERY TODAY, 2023, 28 (09)
  • [46] Alternative Splicing in Lung Cancer
    Pio, Ruben
    Montuenga, Luis M.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (06) : 674 - 678
  • [47] Hallmarks of alternative splicing in cancer
    Oltean, S.
    Bates, D. O.
    ONCOGENE, 2014, 33 (46) : 5311 - 5318
  • [48] Transcriptional elongation and alternative splicing
    Dujardin, Gwendal
    Lafaille, Celina
    Petrillo, Ezequiel
    Buggiano, Valeria
    Gomez Acuna, Luciana I.
    Fiszbein, Ana
    Godoy Herz, Micaela A.
    Nieto Moreno, Nicolas
    Munoz, Manuel J.
    Allo, Mariano
    Schor, Ignacio E.
    Kornblihtt, Alberto R.
    BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS, 2013, 1829 (01): : 134 - 140
  • [49] Alternative splicing and breast cancer
    Dutertre, Martin
    Vagner, Stephan
    Auboeuf, Didier
    RNA BIOLOGY, 2010, 7 (04) : 403 - 411
  • [50] Pharmacology of Modulators of Alternative Splicing
    Bates, David O.
    Morris, Jonathan C.
    Oltean, Sebastian
    Donaldson, Lucy F.
    PHARMACOLOGICAL REVIEWS, 2017, 69 (01) : 63 - 79